Search


Current filters:
Start a new search
Add filters:

Use filters to refine the search results.


Results 21-30 of 180 (Search time: 0.003 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2010Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCRRoss, D.; Branford, S.; Seymour, J.; Schwarer, A.; Arthur, C.; Bartley, P.; Slader, C.; Field, C.; Dang, P.; Filshie, R.; Mills, A.; Grigg, A.; Vaz de Melo, J.; Hughes, T.
2013Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER studyRoss, D.; Branford, S.; Seymour, J.; Schwarer, A.; Arthur, C.; Yeung, D.; Dang, P.; Goyne, J.; Slader, C.; Filshie, R.; Mills, A.; Vaz de Melo, J.; White, D.; Grigg, A.; Hughes, T.
2013Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CMLBranford, S.; Yeung, D.; Ross, D.; Prime, J.; Field, C.; Altamura, H.; Yeoman, A.; Georgievski, J.; Jamison, B.; Phillis, S.; Sullivan, B.; Briggs, N.; Hertzberg, M.; Seymour, J.; Reynolds, J.; Hughes, T.
2007BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteriaBranford, S.; Seymour, J.; Grigg, A.; Arthur, C.; Rudzki, Z.; Lynch, K.; Hughes, T.
2003Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phaseBranford, S.; Rudzki, Z.; Harper, A.; Grigg, A.; Taylor, K.; Durrant, S.; Arthur, C.; Browett, P.; Schwarer, A.; Ma, D.; Seymour, J.; Bradstock, K.; Joske, D.; Lynch, K.; Gathmann, I.; Hughes, T.
2013Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapyAngelini, S.; Soverini, S.; Ravegnini, G.; Barnett, M.; Turrini, E.; Thornquist, M.; Pane, F.; Hughes, T.; White, D.; Radich, J.; Kim, D.; Saglio, G.; Cilloni, D.; Iacobucci, I.; Perini, G.; Woodman, R.; Cantelli-Forti, G.; Baccarani, M.; Hrelia, P.; Martinelli, G.
2014Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 declineBranford, S.; Yeung, D.; Parker, W.; Roberts, N.; Purins, L.; Braley, J.; Altamura, H.; Yeoman, A.; Georgievski, J.; Jamison, B.; Phillis, S.; Donaldson, Z.; Leong, M.; Fletcher, L.; Seymour, J.; Grigg, A.; Ross, D.; Hughes, T.
2006Five-year follow-up of patients receiving imatinib for chronic myeloid leukemiaDruker, B.; Guilhot, F.; O'Brien, S.; Gathmann, I.; Kantarjian, H.; Gattermann, N.; Deininger, M.; Silver, R.; Goldman, J.; Stone, R.; Cervantes, F.; Hochhaus, A.; Powell, B.; Gabrilove, J.; Rousselot, P.; Reiffers, J.; Cornelissen, J.; Hughes, T.; Agis, H.; Fischer, T.; et al.
2017Long-term outcomes of imatinib treatment for chronic myeloid leukemiaHochhaus, A.; Larson, R.; Guilhot, F.; Radich, J.; Branford, S.; Hughes, T.; Baccarani, M.; Deininger, M.; Cervantes, F.; Fujihara, S.; Ortmann, C.; Menssen, H.; Kantarjian, H.; O'Brien, S.; Druker, B.
2010Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNABranford, S.; Hughes, T.